TLX250-CDx

Radionuclide-drug Conjugate (RDC), Breakthrough Therapy Designation granted by the FDA
  • Drug Name: 89Zr-girentuximab
  • Trade Name: TLX250-CDx
  • Indication: Clear cell renal cell carcinoma - Diagnosis